Replimune因1.5亿美元股权发行用于皮肤癌药物而股价大涨

路透中文
Aug 11
BUZZ-Replimune因1.5亿美元股权发行用于皮肤癌药物而股价大涨

8月10日 - ** 周一,Replimune公司(REPL.O)股价飙升14.5%,至13.82美元,此前该公司定价1.5亿美元的后续融资,用于为其近期获批的皮肤癌药物筹集资金

** 总部位于马萨诸塞州沃本的REPL公司于周一早间以每股12.06美元的价格售出约1240万股 (link) 股票,其中包括约270万股预先融资认股权证

** 利林(Leerink)、摩根大通(JP Morgan)和坎托菲茨杰拉德(Cantor Fitzgerald)担任此次发行的联席簿记管理人

** 根据招股说明书,REPL计划将本次发行所得净收益用于支持Tudriqev的商业化上市,并扩大RP2的临床开发计划 (link)

** 周四晚间,美国食品药品监督管理局(FDA)批准 (link) 的Tudriqev与百时美施贵宝(Bristol Myers Squibb)旗下 BMY.N 的Opdivo联合用于治疗既往治疗后肿瘤仍继续生长的晚期黑色素瘤患者

** REPL股价于7月29日收于5.41美元,这是在监管机构顾问小组投票赞成该药物前该股的最后一个收盘价 (link)

** 根据LSEG数据,覆盖该股的8位分析师中有7位给予“强烈买入”或“买入”评级,1位建议“卖出”;目标价中位数为16.50美元

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10